In CLL, the NF-κB pathway is aberrantly active compared to age-matched healthy B cells, and several recurrent genetic mutations that alter NF-κB activity have been reported (25, 26). This evidence concerns the gene NFKB1 and B-cell chronic lymphocytic leukemia.